January 8th 2026
The LAB | Wynwood Miami
MIXiii is Coming to Miami!
Mini MIXiii is IATI's satellite event of the MIXiii Health-Tech.IL Conference, serving as an annual gathering for the Life Science and Health Tech industries in Israel.
IATI is thrilled to announce that, for the second time, Mini MIXiii will be held in Miami on January 8th 2026 at The LAB Miami.
This Symposium will showcase leading Israeli Health-Tech startups, offering them the opportunity to connect with key players in the local Miami health tech ecosystem. Attendees can look forward to a focused and dynamic agenda featuring professional networking opportunities, pitch sessions and one-on-one meetings.
Mini MIXiii is an excellent platform for the global Health-Tech industry to exchange knowledge, network, and drive the industry forward into the future.
Highlights from 2025:
Showcasing Israeli Startup Leaders 2026
Yaky Yanay
CEO &President
Pluri
Tehila Ben Moshe
CEO & Founder
Biond Biologics
Gili Hart
CEO
SpliSense
Eran Ophir
President & CEO
Compugen
Ofer Gonen
CEO
MediWound
Fabian Tenenbaum
CEO
Nectin
Eyal Shamir
CEO
IceCure
Yaacov Michlin
Chairman
OCUVIA
Participating Israeli Health-Tech & Life Science Startups
Biond Biologics
Biond Biologics is a clinical-stage biotech, advancing a innovative pipeline of first-in-class immunotherapies. our key assets:
- BND-67 – A first-in-class anti CD28 shedding antibody that restores T cell activation driving anti-tumor responses. BND-67 is IND ready, Phase 1 initiation in H1 2026
- BND-22 (SAR444881) – A phase 2A first-in-class ILT2 immune checkpoint inhibitor.
- BND-35 – A highly differentiated anti-ILT3 antibody in Phase 1 dose escalation. It blocks all known ILT3 ligands and enhances Fc-effector activity
Compugen
.
NectinTx
Nectin Therapeutics is a biotechnology company pioneering next-generation immuno-oncology and antibody-drug-conjugate therapies to transform cancer treatment. Founded in 2017 from research at the Hebrew University of Jerusalem and the University of Rijeka, Nectin’s innovative mAbs and ADCs target key immune escape mechanisms. Its lead anti-PVR program is in phase 1b for advanced solid tumors with MD Anderson and Merck.
MIXiii Health-Tech.IL 2025 Jerusalem- Highlights
Powered by:
Sponsored by:
Suppurted by:
Israel Advanced Technology Industries Association (IATI)
Fostering the Resilience, Global Competitiveness and the Business Continuity of Israel’s Advanced Technology Industries.
A nonprofit Association of Israel’s advanced tech industry players, IATI is on a mission to foster business certainty and stability for advancing Israel’s high-tech and health-tech industries. This, in turn, furthers national resilience and inclusive economic growth and strengthens Israel’s position as a global innovation leader.
Our members include Israeli tech industry players across all segments – Venture Capital and investment funds, growth and established Israeli companies, R&D centers of Multinational Companies, startups, tech transfer organizations, academic institutions, incubators, innovation centers, hospitals, economic development offices, private investors and service providers.
We connect our members with business opportunities and international stakeholders, building impactful bridges with the global community.
For more information and becoming an IATI Member, please click here